HRP20190289T1 - Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba - Google Patents
Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotrebaInfo
- Publication number
- HRP20190289T1 HRP20190289T1 HRP20190289TT HRP20190289T HRP20190289T1 HR P20190289 T1 HRP20190289 T1 HR P20190289T1 HR P20190289T T HRP20190289T T HR P20190289TT HR P20190289 T HRP20190289 T HR P20190289T HR P20190289 T1 HRP20190289 T1 HR P20190289T1
- Authority
- HR
- Croatia
- Prior art keywords
- stemic
- antigenes
- prostate
- stations
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011118022.6A DE102011118022B4 (de) | 2011-06-30 | 2011-06-30 | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| EP12729996.4A EP2726507B1 (de) | 2011-06-30 | 2012-06-29 | Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung |
| PCT/EP2012/062716 WO2013001065A1 (de) | 2011-06-30 | 2012-06-29 | Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190289T1 true HRP20190289T1 (hr) | 2019-05-03 |
Family
ID=46384405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190289TT HRP20190289T1 (hr) | 2011-06-30 | 2012-06-29 | Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9200078B2 (enExample) |
| EP (2) | EP3505536B1 (enExample) |
| JP (4) | JP2014528696A (enExample) |
| AU (1) | AU2012277784B2 (enExample) |
| CY (1) | CY1121249T1 (enExample) |
| DE (1) | DE102011118022B4 (enExample) |
| DK (1) | DK2726507T3 (enExample) |
| ES (2) | ES2711978T3 (enExample) |
| HR (1) | HRP20190289T1 (enExample) |
| HU (1) | HUE042008T2 (enExample) |
| LT (1) | LT2726507T (enExample) |
| PL (1) | PL2726507T3 (enExample) |
| PT (1) | PT2726507T (enExample) |
| RS (1) | RS58448B1 (enExample) |
| SI (1) | SI2726507T1 (enExample) |
| SM (1) | SMT201900085T1 (enExample) |
| TR (1) | TR201901991T4 (enExample) |
| WO (1) | WO2013001065A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| CA3053010A1 (en) | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| WO2019066093A1 (ko) * | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| AU2019318083A1 (en) | 2018-08-08 | 2021-02-25 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| IL297922A (en) | 2020-05-06 | 2023-01-01 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and clec12a |
| CN116406381A (zh) * | 2020-05-19 | 2023-07-07 | 希望之城 | 工程化抗前列腺干细胞抗原融合蛋白及其用途 |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| WO2024233662A2 (en) * | 2023-05-09 | 2024-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to psca polypeptides |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998040403A1 (en) * | 1997-03-10 | 1998-09-17 | The Regents Of The University Of California | Psca: prostate stem cell antigen |
| US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
| CN1413220A (zh) * | 1999-10-29 | 2003-04-23 | 杰南技术公司 | 抗前列腺干细胞抗原(psca)抗体组合物及其应用方法 |
| SI1673398T1 (sl) * | 2003-10-16 | 2011-05-31 | Micromet Ag | Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule |
| MXPA06013834A (es) * | 2004-05-28 | 2007-03-01 | Agensys Inc | Anticuerpos y moleculas relacionadas que enlazan a proteinas psca. |
| WO2009032949A2 (en) * | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| BRPI0919840B1 (pt) * | 2008-10-01 | 2023-02-28 | Amgen Research (Munich) Gmbh | Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende |
| US20110142811A1 (en) * | 2009-12-16 | 2011-06-16 | Deutsches Krebsforschungszentrum | Measles virus for the elimination of unwanted cell populations |
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
-
2011
- 2011-06-30 DE DE102011118022.6A patent/DE102011118022B4/de not_active Expired - Fee Related
-
2012
- 2012-06-29 LT LTEP12729996.4T patent/LT2726507T/lt unknown
- 2012-06-29 DK DK12729996.4T patent/DK2726507T3/en active
- 2012-06-29 SM SM20190085T patent/SMT201900085T1/it unknown
- 2012-06-29 HR HRP20190289TT patent/HRP20190289T1/hr unknown
- 2012-06-29 ES ES12729996T patent/ES2711978T3/es active Active
- 2012-06-29 HU HUE12729996A patent/HUE042008T2/hu unknown
- 2012-06-29 AU AU2012277784A patent/AU2012277784B2/en not_active Ceased
- 2012-06-29 ES ES18207370T patent/ES2989975T3/es active Active
- 2012-06-29 WO PCT/EP2012/062716 patent/WO2013001065A1/de not_active Ceased
- 2012-06-29 US US14/129,933 patent/US9200078B2/en active Active
- 2012-06-29 EP EP18207370.0A patent/EP3505536B1/de active Active
- 2012-06-29 JP JP2014517736A patent/JP2014528696A/ja active Pending
- 2012-06-29 SI SI201231523T patent/SI2726507T1/sl unknown
- 2012-06-29 TR TR2019/01991T patent/TR201901991T4/tr unknown
- 2012-06-29 EP EP12729996.4A patent/EP2726507B1/de active Active
- 2012-06-29 RS RS20190218A patent/RS58448B1/sr unknown
- 2012-06-29 PL PL12729996T patent/PL2726507T3/pl unknown
- 2012-06-29 PT PT12729996T patent/PT2726507T/pt unknown
-
2017
- 2017-01-12 JP JP2017002983A patent/JP6549622B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-11 CY CY20191100176T patent/CY1121249T1/el unknown
- 2019-06-26 JP JP2019117977A patent/JP6886491B2/ja active Active
-
2021
- 2021-05-13 JP JP2021081553A patent/JP7341185B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE042008T2 (hu) | 2019-06-28 |
| JP6886491B2 (ja) | 2021-06-16 |
| JP2019193652A (ja) | 2019-11-07 |
| JP2021121201A (ja) | 2021-08-26 |
| SI2726507T1 (sl) | 2019-05-31 |
| JP7341185B2 (ja) | 2023-09-08 |
| ES2711978T3 (es) | 2019-05-08 |
| SMT201900085T1 (it) | 2019-05-10 |
| US20140134155A1 (en) | 2014-05-15 |
| TR201901991T4 (tr) | 2019-03-21 |
| CY1121249T1 (el) | 2020-05-29 |
| AU2012277784B2 (en) | 2015-08-20 |
| WO2013001065A1 (de) | 2013-01-03 |
| ES2989975T3 (es) | 2024-11-28 |
| DK2726507T3 (en) | 2019-03-11 |
| LT2726507T (lt) | 2019-04-10 |
| PL2726507T3 (pl) | 2019-06-28 |
| AU2012277784A1 (en) | 2014-02-06 |
| JP2017104113A (ja) | 2017-06-15 |
| DE102011118022A1 (de) | 2013-01-03 |
| JP6549622B2 (ja) | 2019-07-24 |
| EP3505536A1 (de) | 2019-07-03 |
| RS58448B1 (sr) | 2019-04-30 |
| DE102011118022B4 (de) | 2018-01-18 |
| EP3505536C0 (de) | 2024-08-07 |
| PT2726507T (pt) | 2019-02-26 |
| JP2014528696A (ja) | 2014-10-30 |
| EP3505536B1 (de) | 2024-08-07 |
| EP2726507A1 (de) | 2014-05-07 |
| EP2726507B1 (de) | 2018-11-21 |
| US9200078B2 (en) | 2015-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190289T1 (hr) | Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba | |
| IL288203B (en) | Meditopes and meditope-binding antibodies and uses thereof | |
| SI2683406T1 (sl) | Protitelesa ANTI-CD40 in njihova uporaba | |
| IL231777A0 (en) | Antibodies against tl1a and uses thereof | |
| HRP20181515T1 (hr) | Mezenhimne stromalne stanice i upotreba povezana s njima | |
| IL231282A0 (en) | Antibodies to 9pcsk and their uses | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| SI2970456T1 (sl) | Postopki in sestavki za dostavo MRNA-kodiranih protiteles | |
| PL3863288T3 (pl) | Sposoby intra-predykcji i środek nośnikowy | |
| SI2812443T1 (sl) | Protitelesa CD47 in postopki za njihovo uporabo | |
| IL236874B (en) | Anti-kit antibodies and uses thereof | |
| ME03440B (me) | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 | |
| HRP20182098T1 (hr) | Anti-angptl3 antitijela i njihove primjene | |
| HRP20170713T1 (hr) | Bispecifično anti-igf-1r i anti-erbb3 antitijelo | |
| PL2731677T3 (pl) | Przeciwciała wiążące się z OX40 i ich zastosowania | |
| PL2888284T3 (pl) | Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie | |
| HRP20181457T1 (hr) | Anti-htra1 protutijela i postupci uporabe | |
| PL2888593T3 (pl) | Przeciwciała przeciwko rysperydonowi i ich zastosowanie | |
| DK3421470T3 (da) | Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form | |
| HRP20171579T8 (hr) | Antigljivična sredstva i njihova upotreba | |
| PL2887952T3 (pl) | Przeciwciała przeciwko haptenom olanzapinowym i ich zastosowanie | |
| BR112014002716A2 (pt) | anticorpos anti-poliubiquitina e métodos de uso | |
| HUE037212T2 (hu) | Anti-alfa-V integrin ellenanyag prosztatarák kezelésére | |
| IL228403A0 (en) | Compositions comprising anti-influenza antobodies and pseltamivir and uses thereof | |
| IL229958B (en) | Improvements to pumps and components therefor |